AREVA Med Forms High Level Science Advisory Committee
August 25, 2010
August 25, 2010
AREVA and its subsidiary AREVA Med LLC announced today the formation of an advisory committee to support its rapid development.
The committee is composed of five high-level scientists who will provide AREVA Med with strategic advice and scientific guidance in the field of Radioimmunotherapy using 212Pb manufactured by AREVA Med.
The members of the AREVA Med Advisory Committee are:
- Darrell R. Fisher, Ph.D., Medical Physicist and Lead for the Isotope Sciences Program at Pacific Northwest National Laboratory, Richland, Wash.
- Olivier Rixe, M.D., Ph.D., Director of the Experimental Therapeutics Program at the University of Cincinnati, Cincinnati, Ohio
- Brenda M. Sandmaier M.D., Medical Oncologist at Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Wash.
- George Sgouros, Ph.D., Director of the Radiopharmaceutical Dosimetry Section, Johns Hopkins University, Baltimore, Md.
- Christine A. White, M.D., Medical Oncologist and Hematologist, who held several senior positions in the clinical development of the first radio-immunotherapy approved in the US and Europe.
AREVA Med President and CEO Patrick Bourdet said, “I’m delighted and honored that our company is able to involve these world class scientists. This support demonstrates the quality of our work and strategy. It also illustrates the potential of Radioimmunotherapy using 212Pb to treat many types of cancer.”
In nuclear medicine, the development of new treatments is dictated by isotope availability. In March 2010, AREVA Med announced the construction of a Lead-212* industrial production plant that will allow the creation of new targeted therapies for patients.
*Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments.
More information at http://www.arevamed.com/